Neuroprotective agents demonstrated only modest benefits in several clinical trials reported at the American Heart Association’s 23rd Annual Joint Conference on Stroke and Cerebral Circulation [
Orlando, US; February 1998
]. No overall benefit emerged from studies of citicoline, clomethiazole or lubeluzole. However, subgroup analyses identified certain patient populations that did derive significant benefit from treatment and that may represent target treatment groups for future trials, delegates were told at the conference.